In this study, we assessed simultaneously the TIM-3 expression on T cells and AML blasts in patients with non-M3 de novo AML using flow cytometry, and investigated its correlation with clinical outcomes, as well as other clinical parameters, including French-American-British (FAB) classifications, genetic abnormalities and risk stratifications. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.